For more than twenty years, a man in his fifties with no symptoms and a nagging worry about prostate cancer has had a simple route into the system. He could walk into his GP surgery, ask for a PSA blood test, sit through a conversation about false positives and overtreatment, and walk out with an appointment booked. That route has now effectively closed. The Prostate Cancer Risk Management Programme, the framework that guaranteed this access since 2002, has been retired, and the guidance now sitting on NHS.net and in NICE's clinical knowledge summaries hands the final decision to the GP's own assessment of risk.

Ministers insist nothing fundamental has changed. The Department of Health and Social Care's position is that the decision always rested with clinicians, and that the update simply removes ambiguity about who has the final word. There is a technical truth to this. But the distinction between an entitlement a man could invoke and a judgement a doctor might decline to make is not a semantic one. It is the difference between a system organised around informed choice and one organised around triage, and the government has moved from the first toward the second without saying so plainly.

The clinical case for the change is not baseless. PSA testing has always carried a well documented problem: it catches slow-growing tumours that would never have troubled the men who carry them, and the biopsies and treatments that follow often do more harm than the cancer would have. The recommendation in May from the UK National Screening Committee, offering structured PSA testing to men with a BRCA2 variant and relevant family history, points toward a more defensible model, one built on genuine risk stratification rather than blanket access. An expert group convened with the Royal College of General Practitioners is due to publish sharper guidance for assessing that risk in the autumn, which suggests the destination may eventually be more coherent than the current staging post.

What is harder to defend is the timing and the framing. This guidance lands as the NHS is trying to hit a long-standing ambition to diagnose three-quarters of cancers at stage one or two by 2028, a target prostate cancer has struggled against for years precisely because it is so often silent until it is advanced. Removing a route by which concerned but asymptomatic men could self-refer into testing sits awkwardly next to that ambition, whatever the clinical logic behind individual cases. It also lands in general practice, where appointment time is already the scarcest resource in the system, and where GPs are now expected to absorb a judgement call that used to be structural rather than personal. Every asymptomatic man who is told no will have been told no by a named doctor, not by a national programme, and that transfer of exposure from policy to practitioner is not a minor administrative detail.

There is an equity problem buried in this too, one campaigners have already raised. An informed-choice system built on patients requesting a test tends to favour those who already know to ask, typically better-off and more health-literate men. Formal GP discretion could cut either way, depending entirely on how consistently it is applied across practices with wildly different pressures and patient populations. Nothing in the current guidance suggests that consistency has been designed in.

None of this needed to happen through a quietly updated clinical framework. A change of this significance to men's cancer risk, decided without public consultation and communicated through guidance documents rather than through ministers explaining a trade-off to the country, fits an increasingly familiar pattern in how the NHS is now run. Difficult capacity decisions are being reframed as clinical ones and handed downward, to GPs who did not create the constraint and cannot easily explain it to the patient in front of them. The prostate testing debate is not really about PSA thresholds. It is about whether a health service under sustained pressure can keep making rationing decisions this way, one retired programme at a time, without ever having to own the word.